RYTM

SEC source: 0001209191-20-034119 · doc4.xml · nonDerivative · entry 1

Foley Todd · CIK 0001473930 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 2,060,612

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.

F2 · shares: The shares were sold as follows: 10,141 by MPM BioVentures V, L.P. ("BV V") and 394 by MPM Asset Management Investors BV5 LLC ("AM BV5"). MPM BioVentures V GP LLC and MPM BioVentures V LLC ("BV LLC") are the direct and indirect general partners of BV V and BV LLC is the manager of AM BV5. Ansbert Gadicke, Luke Evnin and Todd Foley are the members of BV LLC. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein.

F3 · price: The price in Column 4 is a weighted average sale price. The prices actually received ranged from $20.00 to $20.14. The Reporting Person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

F4 · ownership.nature: Shares are held as follows: 1,983,554 by BV V and 77,058 by AM BV5. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein.

SEC source: 0001209191-20-032719 · doc4.xml · nonDerivative · entry 2

Foley Todd · CIK 0001473930 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 2,071,147

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.

F5 · shares: Shares were sold as follows: 18,436 by BV V and 716 by AM BV5.

F6 · price: The price in Column 4 is a weighted average sale price. The prices actually received ranged from $20.00 to $20.35. The Reporting Person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

F7 · ownership.nature: Shares are held as follows: 1,993,695 by BV V and 77,452 by AM BV5. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein.

SEC source: 0001209191-20-032719 · doc4.xml · nonDerivative · entry 1

Foley Todd · CIK 0001473930 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 2,090,299

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.

F2 · shares: The shares were sold as follows: 9,768 by MPM BioVentures V, L.P. ("BV V") and 380 by MPM Asset Management Investors BV5 LLC ("AM BV5"). MPM BioVentures V GP LLC and MPM BioVentures V LLC ("BV LLC") are the direct and indirect general partners of BV V and BV LLC is the manager of AM BV5. Ansbert Gadicke, Luke Evnin and Todd Foley are the members of BV LLC. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein.

F3 · price: The price in Column 4 is a weighted average sale price. The prices actually received ranged from $20.00 to $20.24. The Reporting Person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

F4 · ownership.nature: Shares are held as follows: 2,012,131 by BV V and 78,168 by AM BV5. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein.

SEC source: 0001209191-20-032086 · doc4.xml · nonDerivative · entry 3

Foley Todd · CIK 0001473930 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 2,100,447

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.

F8 · shares: Shares were sold as follows: 42,760 by BV V and 1,661 by AM BV5.

F9 · price: The price in Column 4 is a weighted average sale price. The prices actually received ranged from $20.12 to $20.74. The Reporting Person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

F10 · ownership.nature: Shares are held as follows: 2,021,899 by BV V and 78,548 by AM BV5. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein.

SEC source: 0001209191-20-032086 · doc4.xml · nonDerivative · entry 2

Foley Todd · CIK 0001473930 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 2,144,868

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.

F5 · shares: Shares were sold as follows: 25,900 by BV V and 1,006 by AM BV5.

F6 · price: The price in Column 4 is a weighted average sale price. The prices actually received ranged from $20.00 to $20.29. The Reporting Person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

F7 · ownership.nature: Shares are held as follows: 2,064,659 by BV V and 80,209 by AM BV5. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein.

SEC source: 0001209191-20-032086 · doc4.xml · nonDerivative · entry 1

Foley Todd · CIK 0001473930 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 2,171,774

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.

F2 · shares: The shares were sold as follows: 24,637 by MPM BioVentures V, L.P. ("BV V") and 957 by MPM Asset Management Investors BV5 LLC ("AM BV5"). MPM BioVentures V GP LLC and MPM BioVentures V LLC ("BV LLC") are the direct and indirect general partners of BV V and BV LLC is the manager of AM BV5. Ansbert Gadicke, Luke Evnin and Todd Foley are the members of BV LLC. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein.

F3 · price: The price in Column 4 is a weighted average sale price. The prices actually received ranged from $20.00 to $20.50. The Reporting Person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

F4 · ownership.nature: Shares are held as follows: 2,090,559 by BV V and 81,215 by AM BV5. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein.

SEC source: 0001209191-20-030985 · doc4.xml · nonDerivative · entry 3

Foley Todd · CIK 0001473930 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 2,197,368

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.

F8 · shares: Shares were sold as follows: 10,133 by BV V and 394 by AM BV5.

F9 · price: The price in Column 4 is a weighted average sale price. The prices actually received ranged from $20.00 to $20.05. The Reporting Person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

F10 · ownership.nature: Shares are held as follows: 2,115,196 by BV V and 82,172 by AM BV5. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein.

SEC source: 0001209191-20-030985 · doc4.xml · nonDerivative · entry 2

Foley Todd · CIK 0001473930 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 2,207,895

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.

F5 · shares: Shares were sold as follows: 2,535 by BV V and 98 by AM BV5.

F6 · price: The price in Column 4 is a weighted average sale price. The prices actually received ranged from $20.00 to $20.02. The Reporting Person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

F7 · ownership.nature: Shares are held as follows: 2,125,329 by BV V and 82,566 by AM BV5. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein.

SEC source: 0001209191-20-030985 · doc4.xml · nonDerivative · entry 1

Foley Todd · CIK 0001473930 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 2,210,528

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.

F2 · shares: The shares were sold as follows: 20,551 by MPM BioVentures V, L.P. ("BV V") and 798 by MPM Asset Management Investors BV5 LLC ("AM BV5"). MPM BioVentures V GP LLC and MPM BioVentures V LLC ("BV LLC") are the direct and indirect general partners of BV V and BV LLC is the manager of AM BV5. Ansbert Gadicke, Luke Evnin and Todd Foley are the members of BV LLC. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein.

F3 · price: The price in Column 4 is a weighted average sale price. The prices actually received ranged from $20.00 to $20.04. The Reporting Person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

F4 · ownership.nature: Shares are held as follows: 2,127,864 by BV V and 82,664 by AM BV5. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein.

SEC source: 0001209191-20-029837 · doc4.xml · nonDerivative · entry 1

Foley Todd · CIK 0001473930 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 2,231,877

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.

F2 · shares: The shares were sold as follows: 1,768 by MPM BioVentures V, L.P. ("BV V") and 69 by MPM Asset Management Investors BV5 LLC ("AM BV5"). MPM BioVentures V GP LLC and MPM BioVentures V LLC ("BV LLC") are the direct and indirect general partners of BV V and BV LLC is the manager of AM BV5. Ansbert Gadicke, Luke Evnin and Todd Foley are the members of BV LLC. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein.

F3 · price: The price in Column 4 is a weighted average sale price. The prices actually received ranged from $20.00 to $20.135. The Reporting Person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

F4 · ownership.nature: Shares are held as follows: 2,148,415 by BV V and 83,462 by AM BV5. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein.

SEC source: 0001209191-20-028594 · doc4.xml · nonDerivative · entry 3

Foley Todd · CIK 0001473930 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 2,233,714

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.

F8 · shares: Shares were sold as follows: 23,432 by BV V and 910 by AM BV5.

F9 · price: The price in Column 4 is a weighted average sale price. The prices actually received ranged from $20.00 to $20.48. The Reporting Person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

F10 · ownership.nature: Shares are held as follows: 2,150,183 by BV V and 83,531 by AM BV5. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein.

SEC source: 0001209191-20-028594 · doc4.xml · nonDerivative · entry 2

Foley Todd · CIK 0001473930 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 2,258,056

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.

F5 · shares: Shares were sold as follows: 21,326 by BV V and 829 by AM BV5.

F6 · price: The price in Column 4 is a weighted average sale price. The prices actually received ranged from $20.00 to $20.55. The Reporting Person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

F7 · ownership.nature: Shares are held as follows: 2,173,615 by BV V and 84,441 by AM BV5. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein.

SEC source: 0001209191-20-028594 · doc4.xml · nonDerivative · entry 1

Foley Todd · CIK 0001473930 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 2,280,211

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.

F2 · shares: The shares were sold as follows: 6,385 by MPM BioVentures V, L.P. ("BV V") and 248 by MPM Asset Management Investors BV5 LLC ("AM BV5"). MPM BioVentures V GP LLC and MPM BioVentures V LLC ("BV LLC") are the direct and indirect general partners of BV V and BV LLC is the manager of AM BV5. Ansbert Gadicke, Luke Evnin and Todd Foley are the members of BV LLC. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein.

F3 · price: The price in Column 4 is a weighted average sale price. The prices actually received ranged from $20.00 to $20.21. The Reporting Person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

F4 · ownership.nature: Shares are held as follows: 2,194,941 by BV V and 85,270 by AM BV5. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein.

SEC source: 0001209191-20-027738 · doc4.xml · nonDerivative · entry 2

Foley Todd · CIK 0001473930 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 2,286,844

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.

F4 · shares: Shares were sold as follows: 193 by BV V and 7 by AM BV5.

F5 · price: The price in Column 4 is a weighted average sale price. The prices actually received ranged from $20.00 to $20.01. The Reporting Person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

F6 · ownership.nature: Shares are held as follows: 2,201,326 by BV V and 85,518 by AM BV5. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein.

SEC source: 0001209191-20-027738 · doc4.xml · nonDerivative · entry 1

Foley Todd · CIK 0001473930 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 2,287,044

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.

F2 · shares: The shares were sold as follows: 1,565 by MPM BioVentures V, L.P. ("BV V") and 61 by MPM Asset Management Investors BV5 LLC ("AM BV5"). MPM BioVentures V GP LLC and MPM BioVentures V LLC ("BV LLC") are the direct and indirect general partners of BV V and BV LLC is the manager of AM BV5. Ansbert Gadicke, Luke Evnin and Todd Foley are the members of BV LLC. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein.

F3 · ownership.nature: Shares are held as follows: 2,201,519 by BV V and 85,525 by AM BV5. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein.

SEC source: 0001209191-20-026323 · doc4.xml · nonDerivative · entry 2

Foley Todd · CIK 0001473930 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 2,288,670

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.

F5 · shares: Shares were sold as follows: 19,634 by BV V and 763 by AM BV5.

F6 · price: The price in Column 4 is a weighted average sale price. The prices actually received ranged from $20.00 to $20.30. The Reporting Person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

F7 · ownership.nature: Shares are held as follows: 2,203,084 by BV V and 85,586 by AM BV5. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein.

SEC source: 0001209191-20-026323 · doc4.xml · nonDerivative · entry 1

Foley Todd · CIK 0001473930 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 2,309,067

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.

F2 · shares: The shares were sold as follows: 15,234 by MPM BioVentures V, L.P. ("BV V") and 592 by MPM Asset Management Investors BV5 LLC ("AM BV5"). MPM BioVentures V GP LLC and MPM BioVentures V LLC ("BV LLC") are the direct and indirect general partners of BV V and BV LLC is the manager of AM BV5. Ansbert Gadicke, Luke Evnin and Todd Foley are the members of BV LLC. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein.

F3 · price: The price in Column 4 is a weighted average sale price. The prices actually received ranged from $20.00 to $20.225. The Reporting Person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

F4 · ownership.nature: Shares are held as follows: 2,222,718 by BV V and 86,349 by AM BV5. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein.

SEC source: 0001209191-20-022104 · doc4.xml · nonDerivative · entry 2

Foley Todd · CIK 0001473930 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 2,324,893

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.

F5 · shares: Shares were sold as follows: 14,908 by BV V and 554 by AM BV5.

F6 · price: The price in Column 4 is a weighted average sale price. The prices actually received ranged from $15.00 to $15.345. The Reporting Person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

F7 · ownership.nature: Shares are held as follows: 2,237,952 by BV V and 86,941 by AM BV5. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein.

SEC source: 0001209191-20-022104 · doc4.xml · nonDerivative · entry 1

Foley Todd · CIK 0001473930 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 2,340,355

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.

F2 · shares: The shares were sold as follows: 18,384 by MPM BioVentures V, L.P. ("BV V") and 724 by MPM Asset Management Investors BV5 LLC ("AM BV5"). MPM BioVentures V GP LLC and MPM BioVentures V LLC ("BV LLC") are the direct and indirect general partners of BV V and BV LLC is the manager of AM BV5. Ansbert Gadicke, Luke Evnin and Todd Foley are the members of BV LLC. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein.

F3 · price: The price in Column 4 is a weighted average sale price. The prices actually received ranged from $15.00 to $15.36. The Reporting Person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

F4 · ownership.nature: Shares are held as follows: 2,252,860 by BV V and 87,495 by AM BV5. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein.

SEC source: 0001104659-20-041297 · a4.xml · derivative · entry 2

Smith Hunter C · CIK 0001636385 · CFO and Interim CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 172,094

Underlying: Common Stock · 3,900 shares

Expires 2027-08-08

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_date: The stock options were granted on August 9, 2017. 25% of the stock options vested and became exercisable on July 31, 2018. 75% of the stock options shall vest in 36 successive, equal monthly installments with the first such installment vesting and becoming exercisable on August 31, 2018.

SEC source: 0001104659-20-041297 · a4.xml · nonDerivative · entry 1

Smith Hunter C · CIK 0001636385 · CFO and Interim CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 29,650

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001209191-20-021729 · doc4.xml · nonDerivative · entry 1

Foley Todd · CIK 0001473930 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 2,359,463

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.

F2 · shares: The shares were sold as follows: 2,213 by MPM BioVentures V, L.P. ("BV V") and 87 by MPM Asset Management Investors BV5 LLC ("AM BV5"). MPM BioVentures V GP LLC and MPM BioVentures V LLC ("BV LLC") are the direct and indirect general partners of BV V and BV LLC is the manager of AM BV5. Ansbert Gadicke, Luke Evnin and Todd Foley are the members of BV LLC. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein.

F3 · price: The price in Column 4 is a weighted average sale price. The prices actually received ranged from $15.00 to $15.34. The Reporting Person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

F4 · ownership.nature: Shares are held as follows: 2,271,244 by BV V and 88,219 by AM BV5. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein.

SEC source: 0001209191-20-020959 · doc4.xml · nonDerivative · entry 1

Foley Todd · CIK 0001473930 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 2,361,763

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.

F2 · shares: Shares were sold as follows: 1,058 by BV V and 42 by AM BV5.

F3 · price: The price in Column 4 is a weighted average sale price. The prices actually received ranged from $15.00 to $15.01. The Reporting Person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

F4 · ownership.nature: Shares are held as follows: 2,273,457 by BV V and 88,306 by AM BV5. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein.

SEC source: 0001209191-20-020304 · doc4.xml · nonDerivative · entry 3

Foley Todd · CIK 0001473930 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 2,362,863

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.

F8 · shares: Shares were sold as follows: 7,889 by BV V and 311 by AM BV5.

F9 · price: The price in Column 4 is a weighted average sale price. The prices actually received ranged from $15.00 to $15.47. The Reporting Person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

F10 · ownership.nature: Shares are held as follows: 2,274,575 by BV V and 88,348 by AM BV5. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein.

SEC source: 0001209191-20-020304 · doc4.xml · nonDerivative · entry 2

Foley Todd · CIK 0001473930 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 2,371,063

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.

F5 · shares: Shares were sold as follows: 12,296 by BV V and 485 by AM BV5.

F6 · price: The price in Column 4 is a weighted average sale price. The prices actually received ranged from $15.00 to $15.61. The Reporting Person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

F7 · ownership.nature: Shares are held as follows: 2,282,404 by BV V and 88,659 by AM BV5. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein.

SEC source: 0001209191-20-020304 · doc4.xml · nonDerivative · entry 1

Foley Todd · CIK 0001473930 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 2,383,844

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.

F2 · shares: The shares were sold as follows: 9,292 by MPM BioVentures V, L.P. ("BV V") and 361 by MPM Asset Management Investors BV5 LLC ("AM BV5"). MPM BioVentures V GP LLC and MPM BioVentures V LLC ("BV LLC") are the direct and indirect general partners of BV V and BV LLC is the manager of AM BV5. Ansbert Gadicke, Luke Evnin and Todd Foley are the members of BV LLC. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein.

F3 · price: The price in Column 4 is a weighted average sale price. The prices actually received ranged from $15.00 to $15.41. The Reporting Person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

F4 · ownership.nature: Shares are held as follows: 2,294,700 by BV V and 89,144 by AM BV5. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein.

SEC source: 0001104659-20-034073 · a4.xml · derivative · entry 2

Smith Hunter C · CIK 0001636385 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 175,994

Underlying: Common Stock · 3,500 shares

Expires 2027-08-08

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_date: The stock options were granted on August 9, 2017. 25% of the stock options vested and became exercisable on July 31, 2018. 75% of the stock options shall vest in 36 successive, equal monthly installments with the first such installment vesting and becoming exercisable on August 31, 2018.

SEC source: 0001104659-20-034073 · a4.xml · nonDerivative · entry 1

Smith Hunter C · CIK 0001636385 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 25,750

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001104659-20-031918 · a4.xml · derivative · entry 2

Gottesdiener Keith Michael · CIK 0001615856 · Director · CEO & President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 207,877

Underlying: Common Stock · 3,408 shares

Expires 2027-04-04

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_date: The stock options vest and become exercisable in 48 successive, equal monthly installments measured from January 6, 2017.

SEC source: 0001104659-20-031918 · a4.xml · nonDerivative · entry 1

Gottesdiener Keith Michael · CIK 0001615856 · Director · CEO & President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 558,250

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · balance_after: Includes 559 shares acquired under the issuer's 2017 Employee Stock Purchase Plan on March 2, 2020.

SEC source: 0001104659-20-022826 · a4.xml · derivative · entry 1

Smith Hunter C · CIK 0001636385 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 82,000

Underlying: Common Stock · 82,000 shares

Expires 2030-02-13

F1 · derivative.exercise_date: This option was granted on February 14, 2020 and the shares underlying this option vest in sixteen equal quarterly installments beginning on May 14, 2020.

SEC source: 0001104659-20-022830 · a4.xml · derivative · entry 1

Desikan Nithya · CIK 0001714105 · Chief Commercial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 80,000

Underlying: Common Stock · 80,000 shares

Expires 2030-02-13

F1 · derivative.exercise_date: This option was granted on February 14, 2020 and the shares underlying this option vest in sixteen equal quarterly installments beginning on May 14, 2020.

SEC source: 0001104659-20-022828 · a4.xml · derivative · entry 1

Kelner Simon · CIK 0001742917 · Chief Human Resources Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 60,000

Underlying: Common Stock · 60,000 shares

Expires 2030-02-13

F1 · derivative.exercise_date: This option was granted on February 14, 2020 and the shares underlying this option vest in sixteen equal quarterly installments beginning on May 14, 2020.

SEC source: 0001104659-20-022827 · a4.xml · derivative · entry 1

Stewart Murray · CIK 0001723450 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 88,000

Underlying: Common Stock · 88,000 shares

Expires 2030-02-13

F1 · derivative.exercise_date: This option was granted on February 14, 2020 and the shares underlying this option vest in sixteen equal quarterly installments beginning on May 14, 2020.

SEC source: 0001104659-20-019193 · a4.xml · derivative · entry 2

Gottesdiener Keith Michael · CIK 0001615856 · Director · CEO & President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 211,286

Underlying: Common Stock · 6,816 shares

Expires 2027-04-04

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_date: The stock options vest and become exercisable in 48 successive, equal monthly installments measured from January 6, 2017.

SEC source: 0001104659-20-019193 · a4.xml · nonDerivative · entry 1

Gottesdiener Keith Michael · CIK 0001615856 · Director · CEO & President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 554,283

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · balance_after: Includes 553 shares acquired under the issuer's 2017 Employee stock purchase plan on September 3, 2019.

SEC source: 0001104659-20-008015 · a4.xml · derivative · entry 2

Smith Hunter C · CIK 0001636385 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 179,494

Underlying: Common Stock · 6,250 shares

Expires 2027-08-08

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_date: The stock options were granted on August 9, 2017. 25% of the stock options vested and became exercisable on July 31, 2018. 75% of the stock options shall vest in 36 successive, equal monthly installments with the first such installment vesting and becoming exercisable on August 31, 2018.

SEC source: 0001104659-20-008015 · a4.xml · nonDerivative · entry 1

Smith Hunter C · CIK 0001636385 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 22,250

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001104659-20-003024 · a4.xml · derivative · entry 2

Gottesdiener Keith Michael · CIK 0001615856 · Director · CEO & President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 84,208

Underlying: Common Stock · 33,072 shares

Expires 2025-11-16

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_date: The stock options vest and become exercisable in 48 successive, equal monthly installments measured from August 3, 2015.

SEC source: 0001104659-20-003024 · a4.xml · nonDerivative · entry 1

Gottesdiener Keith Michael · CIK 0001615856 · Director · CEO & President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 546,914

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001104659-19-077301 · a4.xml · derivative · entry 3

Desikan Nithya · CIK 0001714105 · Chief Commercial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 137,495

Underlying: Common Stock · 35,181 shares

Expires 2027-08-08

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_date: The stock options were granted on August 9, 2017. 32,715 of the total shares vested and became exercisable immediately upon grant. 25% of the remaining stock options vested and became exercisable on July 23, 2018. 75% of the remaining stock options shall vest in 36 successive, equal monthly installments with the first such installment vesting and becoming exercisable on August 23, 2018.

SEC source: 0001104659-19-077301 · a4.xml · nonDerivative · entry 2

Desikan Nithya · CIK 0001714105 · Chief Commercial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 29,068

F1 · kind: On December 27, 2019, Ms. Desikan sold 35,181 shares pursuant to a plan of disposition adopted in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended.

F2 · price: This transaction was executed in multiple trades at prices ranging from $22.41 to $23.06, inclusive; the price reported above reflects the weighted average sale price. Ms. Desikan hereby undertakes to provide to the Securities and Exchange Commission staff, the issuer or any security holder of the issuer, upon request, full information regarding the number of shares and prices at which the transaction was effected.

SEC source: 0001104659-19-077301 · a4.xml · nonDerivative · entry 1

Desikan Nithya · CIK 0001714105 · Chief Commercial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 64,249

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001209191-19-060391 · doc4.xml · nonDerivative · entry 2

Foley Todd · CIK 0001473930 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 2,393,497

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.

F5 · shares: Shares were sold as follows: 3,621 by BV V and 141 by AM BV5.

F6 · price: The price in Column 4 is a weighted average sale price. The prices actually received ranged from $25.00 to $25.06. The Reporting Person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

F7 · ownership.nature: Shares are held as follows: 2,303,992 by BV V and 89,505 by AM BV5. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein.

SEC source: 0001209191-19-060391 · doc4.xml · nonDerivative · entry 1

Foley Todd · CIK 0001473930 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 2,397,259

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.

F2 · shares: The shares were sold as follows: 13,091 by MPM BioVentures V, L.P. ("BV V") and 509 by MPM Asset Management Investors BV5 LLC ("AM BV5"). MPM BioVentures V GP LLC and MPM BioVentures V LLC ("BV LLC") are the direct and indirect general partners of BV V and BV LLC is the manager of AM BV5. Ansbert Gadicke, Luke Evnin and Todd Foley are the members of BV LLC. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein.

F3 · price: The price in Column 4 is a weighted average sale price. The prices actually received ranged from $25.00 to $25.50. The Reporting Person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

F4 · ownership.nature: Shares are held as follows: 2,307,613 by BV V and 89,646 by AM BV5. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein.

SEC source: 0001209191-19-060024 · doc4.xml · nonDerivative · entry 2

Foley Todd · CIK 0001473930 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 2,410,859

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.

F5 · shares: Shares were sold as follows: 40,274 by BV V and 1,565 by AM BV5.

F6 · price: The price in Column 4 is a weighted average sale price. The prices actually received ranged from $25.00 to $25.83. The Reporting Person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

F7 · ownership.nature: Shares are held as follows: 2,320,704 by BV V and 90,155 by AM BV5. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein.

SEC source: 0001209191-19-060024 · doc4.xml · nonDerivative · entry 1

Foley Todd · CIK 0001473930 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 2,452,698

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.

F2 · shares: The shares were sold as follows: 21,365 by MPM BioVentures V, L.P. ("BV V") and 830 by MPM Asset Management Investors BV5 LLC ("AM BV5"). MPM BioVentures V GP LLC and MPM BioVentures V LLC ("BV LLC") are the direct and indirect general partners of BV V and BV LLC is the manager of AM BV5. Ansbert Gadicke, Luke Evnin and Todd Foley are the members of BV LLC. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein.

F3 · price: The price in Column 4 is a weighted average sale price. The prices actually received ranged from $25.00 to $25.31. The Reporting Person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

F4 · ownership.nature: Shares are held as follows: 2,360,978 by BV V and 91,720 by AM BV5. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein.

SEC source: 0001209191-19-058905 · doc4.xml · nonDerivative · entry 2

Foley Todd · CIK 0001473930 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 2,474,893

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.

F5 · shares: Shares were sold as follows: 16,151 by BV V and 626 by AM BV5.

F6 · ownership.nature: Shares are held as follows: 2,382,343 by BV V and 92,550 by AM BV5. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein.

SEC source: 0001209191-19-058905 · doc4.xml · nonDerivative · entry 1

Foley Todd · CIK 0001473930 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 2,491,670

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.

F2 · shares: The shares were sold as follows: 24,417 by MPM BioVentures V, L.P. ("BV V") and 949 by MPM Asset Management Investors BV5 LLC ("AM BV5"). MPM BioVentures V GP LLC and MPM BioVentures V LLC ("BV LLC") are the direct and indirect general partners of BV V and BV LLC is the manager of AM BV5. Ansbert Gadicke, Luke Evnin and Todd Foley are the members of BV LLC. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein.

F3 · price: The price in Column 4 is a weighted average sale price. The prices actually received ranged from $21.63 to $22.42. The Reporting Person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

F4 · ownership.nature: Shares are held as follows: 2,398,494 by BV V and 93,176 by AM BV5. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein.

SEC source: 0001209191-19-058413 · doc4.xml · nonDerivative · entry 3

Foley Todd · CIK 0001473930 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 2,517,036

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.

F8 · shares: Shares were sold as follows: 17,672 by BV V and 687 by AM BV5.

F9 · price: The price in Column 4 is a weighted average sale price. The prices actually received ranged from $22.36 to $22.95. The Reporting Person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

F10 · ownership.nature: Shares are held as follows: 2,422,911 by BV V and 94,125 by AM BV5. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein.